O. I. Illarionova

O. I. Illarionova

Auto-generated profile, based on publicly available information

O. I. Illarionova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
EME. V. Mikhailova
E. V. Mikhailova
TVT. Yu. Verzhbitskaya
T. Yu. Verzhbitskaya
JRJ. V. Roumiantseva
J. V. Roumiantseva
OIO. I. Illarionova
O. I. Illarionova
ASAlexandra Semchenkova
Alexandra Semchenkova
ТВТ. Ю. Вержбицкая
Т. Ю. Вержбицкая
Minimal residual disease (MRD) monitoring by flow cytometry at the end of induction therapy is one of the key ways of a prognosis assessment in patients with acute lymphoblastic leukemia (ALL). In B-cell precursor ALL (BCP–ALL), this method of MRD detection is complicated due to the immunophenotypic similarity between leukemic cells and normal B-cell precursors (BCPs). A decrease in intensity of induction therapy can lead to a more frequent appearance of normal BCPs in the bone marrow, which significantly complicates the MRD monitoring. Aim: to assess the incidence of normal BCPs in bone marrow on the 36th day of induction therapy with two different regimens of glucocorticoid (GC) administration according to ALL-MB 2015 protocol. This study was approved by the Independent Ethical Committee and the Academic Council of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation. The study included 220 patients with BCP-ALL who were randomized to two types of GC-based induction therapy: a continuous administration of dexamethasone (n = 139) and an intermittent regimen with a 1-week dexamethasone therapy stop (n = 81). On the 36th day of induction therapy, MRD and normal BCPs were quantified in bone marrow samples by flow cytometry. On the 36th day of treatment, 43.2% of BCP(+) samples were established in the intermittent-therapy group, and 27.3% in the continuous-therapy group (p = 0.016). Comparison of the BCP level in BCP(+) samples revealed the more equitable distribution of BCPs at different developmental stages in the intermittent-therapy group, meanwhile mainly the immature BCPs in a quantity of less than 0.01% were found in the continuous-therapy group. Reduced-intensity induction therapy for patients with BCP-ALL leads to a noticeable increase of normal BCPs in bone marrow at the end of this treatment stage. A higher rate of BCP(+) bone marrow samples hinder the MRD detection due to the immunophenotypic similarity of BCPs and leukemic cells.

8 July 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
EMEkaterina Mikhailova
Ekaterina Mikhailova
OIO. I. Illarionova
O. I. Illarionova
MMMichael Maschan
Michael Maschan
GNG. A. Novichkova
G. A. Novichkova
AKA. I. Karachunskiy
A. I. Karachunskiy
APAlexander popov
Alexander popov
Multicolor flow cytometry is now routinely used in laboratory practice for the minimal residual disease (MRD) monitoring in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Wide application of CD19-directed immunotherapy leads to frequent loss of CD19 expression, that hampers significantly the flow cytometric MRD detection methodology. We developed an antibody panel and data analysis algorithm for multicolor flow cytometry, which is a reliable method for MRD detection in patients with BCP-ALL treated with CD19-directed therapy. We recommend a single-tube 11-color panel for MRD detection, which is adapted for the case of possible CD19 loss. Based on patterns of antigen expression changes and the relative expansion of normal CD19-negative BCPs, guidelines for multicolored flow cytometry data analysis and interpretation are established. The recommended approach is reliable tool for therapy response monitoring displaying the same effectiveness with the more laborious and costly molecular techniques.

12 September 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Closed access
MAMaxim Aleksenko
Maxim Aleksenko
OIO. I. Illarionova
O. I. Illarionova
NVN/ Yu. Verzhbitskaya
N/ Yu. Verzhbitskaya
EZElena Zerkalenkova
Elena Zerkalenkova
INI. A. Novikova
I. A. Novikova
APAlexander popov
Alexander popov
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia, in which the bone marrow produce increased numbers of immature abnormal megakaryoblasts. AMKL is rare both in children and adults, but is the most frequent subtype of acute myeloid leukemia (AML) in children with Down syndrome. Morphological diagnosis of this disease could be complicated, thus flow cytometry plays a crucial role in the diagnostics of AMKL. The aim of the present study was to investigate the immunophenotypic characteristics of AMKL in children. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The study group included 103 patients with AMKL. Antigen expression profile was assessed by multicolor flow cytometry. We identified three groups of patients according to different levels of CD45 expression, and in majority of patients (74%) high level of CD45 expression was detected. Significant immunophenotypic differences between these groups were found. In 56% of patients trisomy of 21 chromosome was detected. Among these patients, 86% belonged to group of high CD45 expression. Moreover, children with trisomy 21 represented the majority in the group with high level of CD45 expression (64%). Also, there were found several significant differences between patients with and without trisomy 21 within the group of high CD45 expression. This study demonstrated the wide immunophenotypic heterogeneity of AMKL. In general, the revealed diversity obviously reflects the biological heterogeneity of this AML subtype.

29 June 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ASA. S. Sharlai
A. S. Sharlai
OIO. I. Illarionova
O. I. Illarionova
YFY. G. Fediukova
Y. G. Fediukova
TVT. Yu. Verzhbitskaya
T. Yu. Verzhbitskaya
LFL. G. Fechina
L. G. Fechina
ТВТ. Ю. Вержбицкая
Т. Ю. Вержбицкая
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a recently recognized T-ymphoblastic leukemia subgroup with poor prognosis and high-risk of relapse. ETP-ALL subgroup is characterized by unique gene expression and particular cell surface markers profile. Nevertheless, this group cannot be easily detected due to its biological heterogeneity. The aim of the present study was to explore the immunophenotypic characteristics of early T-cell precursor acute lymphoblastic leukemia in ETP-ALL patient. The study group consisted of 64 patients with ETP-ALL. 380 patients with other variants of T-ALL were included to the control group. The antigen expression profile was assessed by multicolor flow cytometry. TI and TII immunological variants were detected in the group of patients with ETP-ALL. Cell markers expression level was determined in both groups. In the study group of ETP-ALL patients CD11a expression was more specific to TII-ALL, while CD33 expression – for TI-ALL. This study allowed to characterize group of patients with ETP-ALL and detected immunophenotypic heterogeneity. More interlaboratory studies are needed for understanding immunological and molecular genetic features ETP-ALL. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology.

10 January 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Closed access
AAA. S. Aksenova
A. S. Aksenova
OIO. I. Illarionova
O. I. Illarionova
DLD. V. Litvinov
D. V. Litvinov
SKS. A. Kashpor
S. A. Kashpor
APAlexander popov
Alexander popov
CD1a antigen expression is an important prognostic factor in T-lineage acute lymphoblastic leukemia (T-ALL), thus standardized approach for this antigen expression detection is crucial for multicenter trials. The use of different antibodies in laboratories could lead to wrong decisions for patients management. The aim of the present study was to analyze the results of flow cytometric bone marrow investigation in children with T-ALL using different CD1a-directed antibodies. The bone marrow samples from 31 children (8 girls and 23 boys) with T-ALL aged from 1 to 16 years (median age 7) were studied by multicolor flow cytometry including two different antibodies against CD1a (BL6 и SK9). There were no significant differences in the immunophenotyping results. However, the CD1a-positivity of tumor cell population was visible in the dot plot better when BL6 antibody was used. In addition, two patients with discordant CD1a expression data were founded. Therefore, we antibody BL6 was recommended for routine T-ALL immunophenotyping.

8 October 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IDIrina Demina
Irina Demina
SKS. A. Kashpor
S. A. Kashpor
OIO. I. Illarionova
O. I. Illarionova
MDM. E. Dubrovina
M. E. Dubrovina
ADA. A. Dudorova
A. A. Dudorova
ЮОЮ. В. Ольшанская
Ю. В. Ольшанская
The diagnosis of rare hematological disorders requires a comprehensive clinical and laboratory investigation with careful interpretation of all test results. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one of such rare entities. We have performed a retrospective analysis of the results of immunophenotyping, cytomorphology and cytogenetics of bone marrow tumor cells from 5 patients with BPDCN aged from 8 to 51 years. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. No specific characteristics of blasts were found. No correlation with the treatment and outcomes was noted as well: 3 patients died of progression or relapse (2 and 1, respectively). Bone marrow immunophenotyping is probably the most valuable laboratory test which allows physicians to establish the proper diagnosis in the absence of skin lesions. Flow cytometry immunophenotyping is the only technique used to determine the antigen profile that enables us to distinguish normal plasmacytoid dendritic cells from tumor ones by the presence (or absence) of the expression of CD2, CD7, CD38, CD56, CD303 etc. In the present paper, we provide a detailed description of five cases of BPDCN and main methods for flow cytometry data analysis. The parents of the patients agreed to use the information, including photos of children, in scientific research and publications.